Contineum Therapeutics Inc
CTNM
Company Profile
Business description
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Contact
3565 General Atomics Court
Suite 200
San DiegoCA92121
USAT: +1 858 333-5280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
41
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,759.90 | 69.00 | 0.79% |
| CAC 40 | 7,763.84 | 26.64 | 0.34% |
| DAX 40 | 24,091.62 | 160.95 | 0.67% |
| Dow JONES (US) | 42,519.64 | 214.16 | 0.51% |
| FTSE 100 | 8,787.02 | 12.76 | 0.15% |
| HKSE | 23,653.97 | 141.48 | 0.60% |
| NASDAQ | 19,398.96 | 156.34 | 0.81% |
| Nikkei 225 | 37,747.19 | 300.38 | 0.80% |
| NZX 50 Index | 12,494.71 | 167.48 | 1.36% |
| S&P 500 | 5,970.37 | 34.43 | 0.58% |
| S&P/ASX 200 | 8,531.90 | 65.20 | 0.77% |
| SSE Composite Index | 3,373.57 | 11.59 | 0.34% |